Selected article for: "HIV human immunodeficiency virus and human immunodeficiency virus"

Author: CV Herst; S Burkholz; J Sidney; A Sette; PE Harris; S Massey; T Brasel; E Cunha-Neto; DS Rosa; WCH Chao; R Carback; T Hodge; L Wang; S Ciotlos; P Lloyd; R Rubsamen
Title: An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design
  • Document date: 2020_2_27
  • ID: i55tm3hh_3
    Snippet: Human pathogen-derived peptide antigens that are also recognized by C57BL/6 T-cells have been previously described. These include peptides from vesicular stomatitis virus (VSV) RGYVYQGL [68] , and human immunodeficiency virus (HIV) RGPGRAFVTI [5] . The existence of such epitopes makes a range of preclinical vaccine experiments possible without having to rely on non-human pri- 35 mates and expensive and complex-to-manage humanized mouse models. Wi.....
    Document: Human pathogen-derived peptide antigens that are also recognized by C57BL/6 T-cells have been previously described. These include peptides from vesicular stomatitis virus (VSV) RGYVYQGL [68] , and human immunodeficiency virus (HIV) RGPGRAFVTI [5] . The existence of such epitopes makes a range of preclinical vaccine experiments possible without having to rely on non-human pri- 35 mates and expensive and complex-to-manage humanized mouse models. Wilson et al. showed that the EBOV nucleoprotein (NP) is an immunogen that provides protective, CTL-mediated immunity against EBOV in a C57BL/6 mouse model and that this protection was conferred by a peptide sequence within Ebola Zaire: NP43-53 (VYQVNNLEEIC) [73] . Wilson et al. came to this conclusion 40 based on studying splenocytes harvested from mice vaccinated with Ebola Zaire NP using a Venezuelan equine encephalitis (VEE) vector. Their experiments showed that splenocytes from the vaccinated mice re-stimulated with NP43-53

    Search related documents:
    Co phrase search for related documents